PremiumCompany AnnouncementsProQR Reports Q1 2025 Financial Results Amid Rising R&D Costs ProQR Therapeutics reports Q1 EPS (EUR 0.10) vs (EUR 0.09) last year PRQR Upcoming Earnings Report: What to Expect? PremiumThe FlyProQR Therapeutics appoints Hom as CFO, Lopez as CMO ProQR Therapeutics Advances RNA Editing Pipeline ProQR’s Axiomer Technology and AX-0810: A Promising Buy Rating with Increased Price Target PremiumRatingsProQR’s Undervalued Potential: Buy Rating on Promising Pipeline and Market Opportunity ProQR Therapeutics upgraded to Buy from Neutral at Citi PRQR Earnings this Week: How Will it Perform?